Core Viewpoint - Boston Scientific Corporation (NYSE:BSX) has experienced significant underperformance in the stock market, attributed to increased competition and macroeconomic uncertainties, particularly related to tariff investigations on medical devices [1][3]. Company Overview - Boston Scientific Corporation manufactures medical devices across various fields, including cardiology, neurology, and urology, with products such as heart-monitoring implants and spinal cord stimulators [3]. Market Position and Challenges - The company is facing challenges due to a Section 232 tariff investigation announced by the Trump administration, which has increased macro uncertainty in the medical device sector [3]. - Despite these challenges, Boston Scientific is well-positioned to manage tariffs due to its diverse supply chain and increased manufacturing footprint in the U.S. post-COVID [3]. Financial Outlook - Management has set long-term targets of 10% organic revenue growth, 50 basis points of annual margin expansion, and double-digit EPS growth through 2028, indicating a positive outlook for the company [3]. - The company has a strong pricing power and has largely mitigated the impact of tariffs thus far [3]. Growth Drivers - Boston Scientific's diversified growth profile across cardiology, electrophysiology, endoscopy, and urology franchises supports its favorable view in the market [3]. - The introduction of Farapulse, a pulsed-field ablation technology, is expected to drive significant growth in the electrophysiology segment in the coming years [3].